IRX2 (iroquois homeobox 2) is a transcription factor that functions as both a DNA-binding transcriptional regulator and repressor of RNA polymerase II-dependent genes 1. As a homeobox gene, IRX2 plays critical roles in developmental processes, including neuron differentiation and cell development [GO Annotations]. IRX2 regulates transcription through sequence-specific DNA binding and chr5 interactions [GO Annotations]. Mechanistically, IRX2 exhibits context-dependent regulatory functions. In pediatric pilocytic astrocytoma, MEK-mediated proliferation occurs through IRX2-controlled CTNNB1 (β-catenin) transcription 1. In endometrial carcinoma, IRX2 acts as a transcriptional repressor of RUVBL1, with IRX2 promoter methylation (at sites cg26333652 and cg11793269) suppressing its expression and facilitating tumor progression 2. In osteosarcoma, IRX2 promotes cell proliferation and invasion by activating the PI3K/AKT signaling pathway, leading to upregulation of MMP2, MMP9, and VEGF 34. Clinically, IRX2 demonstrates cancer-type-specific dysregulation. It is frequently amplified in soft tissue sarcomas, particularly malignant peripheral nerve sheath tumors, with expression correlating with gene copy number 5. IRX2 is aberrantly expressed in B-cell precursor acute lymphoblastic leukemia, correlating with TCF3/E2A-fusion subtypes 6. During normal development, IRX2 marks digit formation during limb development 7. These findings suggest IRX2 as a potential therapeutic target across multiple malignancies.